UK markets closed
NIKKEI 225
29,106.01 +505.60 (+1.77%) HANG SENG
26,038.27 -93.76 (-0.36%) CRUDE OIL
84.44 -0.21 (-0.25%) GOLD FUTURES
1,794.10 -12.70 (-0.70%) DOW
35,756.88 +15.73 (+0.04%) BTC-GBP
43,767.58 -2,025.18 (-4.42%)
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
67.73+0.06 (+0.09%)
At close: 4:00PM EDT
67.57 -0.16 (-0.24%)
After hours: 05:57PM EDT
After hours: 05:57PM EDT
| Previous close | 67.67 |
| Open | 67.97 |
| Bid | 67.73 x 900 |
| Ask | 68.32 x 1200 |
| Day's range | 67.70 - 68.39 |
| 52-week range | 56.56 - 73.34 |
| Volume | 4,675,096 |
| Avg. volume | 6,238,138 |
| Market cap | 84.921B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 16.58 |
| EPS (TTM) | 4.09 |
| Earnings date | 28 Oct 2021 |
| Forward dividend & yield | 2.84 (4.20%) |
| Ex-dividend date | 14 Sept 2021 |
| 1y target est | 76.03 |
- Business Wire
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
FOSTER CITY, Calif. & KENILWORTH, N.J., October 26, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy.
- Zacks
Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.
- Zacks
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
© 2021 Verizon Media. All rights reserved.
